DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for gestational trophoblastic neoplasm — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGestational trophoblastic neoplasm maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for gestational trophoblastic neoplasm is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
dihydrofolate reductase (DHFR) — DHFR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ndpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4M6J · 1.201 Å · ligand NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NDP). Experimental structure, not a prediction.
What the evidence adds up to
Most patients with gestational trophoblastic neoplasia are cured with chemotherapy. For low-risk disease, single-agent chemotherapy is standard; for high-risk disease, combination chemotherapy using etoposide, methotrexate and actinomycin D alternating with cyclophosphamide and oncovine is used. Survival in high-risk patients is 86%, and virtually all low-risk patients are cured. A 2007 review notes that for resistant disease, paclitaxel-containing regimens appear better tolerated than older alternatives, but optimisation of treatment for drug resistance remains a key challenge.
A 2010 review states that some patients still suffer resistant disease and may die, and that new therapeutic agents are needed to reduce toxicity and treat refractory disease. It identifies molecular targeted treatment as an avenue, but notes the biology of gestational trophoblastic neoplasia is not well understood. A 2020 clinical case reports successful treatment of a single patient with multidrug resistant disease using the GEMOX regimen (gemcitabine and oxaliplatin). No sample size or response rate beyond that single case is given.
The 2007 and 2010 reviews both note that progress has been made in understanding genetic changes and human chorionic gonadotrophin monitoring, but neither reports a new drug that has changed outcomes in a controlled trial. The 2020 case is a single patient, not a trial. What is still missing is a prospective trial of GEMOX or any targeted agent in resistant disease, patient stratification beyond the low-risk/high-risk binary, and funding for the biological studies needed to identify reliable therapeutic targets.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Oncology · 2007 · 112 citations
Gestational trophoblastic neoplasia management: an update
AbstractPURPOSE OF REVIEW: Gestational trophoblastic neoplasia represents the malignant end of the gestational trophoblastic disease spectrum. This review updates readers on developments in the management of gestational trophoblastic neoplasia over the past few years. RECENT FINDINGS: Progress has been made in elucidating the genetic changes that give rise to gestational trophoblastic neoplasia. The importance of accurate human chorionic gonadotrophin monitoring and the types of human chorionic gonadotrophin produced in cancer are also topical. Fortunately, most patients are cured with chemotherapy, and the choice of treatment schedule according to low-risk and high-risk prognostic groups is relatively unchanged. Indeed, most patients with low-risk gestational trophoblastic neoplasia are treated with single agent chemotherapy, and those who have high-risk disease with combination chemotherapy using etoposide, methotrexate and actinomycin D, alternating with cyclophosphamide and oncovine. For resistant disease, new paclitaxel-containing regimens appear better tolerated than etoposide and cisplatin alternating weekly with etoposide, methotrexate and actinomycin D. SUMMARY: Prognosis in gestational trophoblastic neoplasia is now excellent following treatment. Virtually all patients with low-risk disease are cured, and survival is now 86% in high-risk patients. Optimization of treatment strategies for those who develop drug resistance remains a key challenge.
Anti-Cancer Agents in Medicinal Chemistry · 2010 · 3 citations
Gestational Trophoblastic Neoplasia, an Ancient Disease: New Light and Potential Therapeutic Targets
AbstractGestational trophoblastic neoplasia is a rare malignancy, which can occur after any type of pregnancy. The incidence varies according to the geographical location and ethnic origin. Although most patients with gestational trophoblastic neoplasia are cured by conventional chemotherapy and surgery, some suffer resistant disease and may die. New therapeutic agents are needed to reduce the toxicity associated with conventional chemotherapy and treat those with resistant or refractory disease. Molecular targeted treatment provides an exciting avenue, however, the biology of gestational trophoblastic neoplasia is not well understood. This review briefly summarises the recent advances in understanding the pathogenesis and molecular biology of this group of diseases and sheds light on molecules that could provide potential therapeutic targets.
Russian Journal of Oncology · 2020 · 0 citations · open access
Successful treatment of a chemo-resistant gestational trophoblastic neoplasia using GEMOX. Clinical case
AbstractGestational trophoblastic neoplasia is a rare malignancy. The main treatment approach is chemotherapy. Almost all patients can be cured if the diagnosis is established timely and adequate treatment is provided in specialized centers.
 In a small part of patients, the tumor progresses despite the use of all standard chemotherapy regimens. Treatment of such patients is difficult for all oncologists, including ones working in specialized centers for the treatment of gestational trophoblastic neoplasia.
 This article presents a clinical case of the successful treatment of a patient with multidrug resistant gestational trophoblastic neoplasia using GEMOX regimen.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
